RenovoRx (NASDAQ:RNXT) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of RenovoRx (NASDAQ:RNXT) from a hold rating to a sell rating in a report issued on Monday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, RenovoRx currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

RenovoRx Stock Up 3.4%

Shares of RenovoRx stock opened at $1.22 on Monday. The firm’s 50 day moving average is $1.50 and its 200 day moving average is $1.11. RenovoRx has a 1 year low of $0.70 and a 1 year high of $2.59.

RenovoRx (NASDAQ:RNXT) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.06 million. As a group, analysts predict that RenovoRx will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in RenovoRx stock. T3 Companies LLC bought a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned 0.21% of RenovoRx at the end of the most recent reporting period. Institutional investors own 3.10% of the company’s stock.

Key Headlines Impacting RenovoRx

These are some of the RNXT headlines that stood out recently:

• Neutral Sentiment: A report described short interest as having increased, but listed total short interest at zero shares and a short-interest ratio of 0.0 days. The figures suggest little reported short positioning, though the wording and data appear inconsistent. MarketBeat report on RNXT
• Negative Sentiment: HC Wainwright lowered its EPS estimates for late 2026 and 2027, as well as FY2028–FY2030. Notable revisions include FY2026 loss widening to $0.29 per share from $0.21, FY2027 loss to $0.19 from $0.04, and FY2028 shifting from expected $0.08 profit to a $0.03 loss. It also cut projected profits for FY2029 and FY2030, indicating a weaker earnings outlook that could weigh on investor sentiment. MarketBeat report on HC Wainwright estimates

RenovoRx Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.